【央视新闻】我国新型基因治疗策略有望推动孤独症、癫痫等疾病治疗

Core Viewpoint - AAVLINK is a novel gene therapy strategy developed by the Shenzhen Institute of Advanced Technology, which addresses the challenge of efficiently delivering long genes using AAV vectors, potentially advancing clinical applications for neurodevelopmental disorders and other genetic diseases [3][4]. Group 1: Background and Significance - Over 7,000 rare diseases have been identified globally, most of which are caused by genetic mutations and lack effective treatments, posing significant challenges in medicine [3]. - Gene therapy offers new hope for treating rare and hereditary diseases by repairing, replacing, or inhibiting pathogenic genes [3]. Group 2: AAVLINK Methodology - The AAVLINK method innovatively splits long genes into two segments, each packaged in separate AAV vectors; one carries a gene segment with a lox site, while the other carries the second segment and a Cre recombinase gene [4]. - Upon entering cells, the Cre recombinase recognizes the lox sites, allowing for precise reassembly of the split genes, leading to the expression of a full-length functional protein [4]. Group 3: Safety and Efficacy - AAVLINK 2.0 addresses potential issues of gene rearrangement and immune responses, enhancing the safety of clinical applications [4]. - Research indicates that this technology can efficiently reconstruct large gene segments in various cell types without producing truncated proteins, showing significantly higher recombination efficiency compared to traditional methods [4]. - Animal studies demonstrate that AAVLINK can effectively improve behavioral and epileptic phenotypes in relevant mouse models [4]. Group 4: Future Directions - The research team plans to further explore the systemic delivery efficiency of AAVLINK, investigate its mechanisms, and establish disease models, with aims for systematic validation in primate models and preclinical studies to facilitate the technology's translation into clinical practice [4].